Anti-CSF2/GM-CSF Antibody (Lenzilumab)
Catalog No.
F1008
Anti-CSF2/GM-CSF Antibody (Lenzilumab)
Featured Products
Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF that can be used in COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) research.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
1229575-09-0
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Lenzilumab (USAN/INN), KB-003
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P04141
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human GM CSF Nhis at 2 ug/mL can bind Anti-CSF2/GM-CSF Antibody (Lenzilumab)
CSF2 / GM-CSF
Please avoid freeze-thaw cycles.